Monte Rosa Therapeutics (GLUE) Consolidated Net Income (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Consolidated Net Income of -$44.6 million for Q1 2026, down 195.02% year-over-year from $46.9 million in Q1 2025, and down 51.08% quarter-over-quarter from -$29.5 million in Q4 2025.
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Consolidated Net Income (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Consolidated Net Income history runs 7 years deep, the most recent figure standing at -$44.6 million for Q1 2026.
- In Q1 2026, Consolidated Net Income fell 195.02% year-over-year to -$44.6 million; the TTM figure through Mar 2026 stood at -$113.4 million (down 583.65% YoY), while the FY2025 annual figure was -$22.0 million, up 60.33% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$44.6 million, down from -$29.5 million in the prior quarter.
- The five-year high for Consolidated Net Income was $46.9 million in Q1 2025, with the low at -$64.8 million in Q1 2022.
- The 5-year median for Consolidated Net Income is -$30.3 million (2024), against an average of -$23.9 million.
- The sharpest annual moves came in 2022 and 2025: Consolidated Net Income plunged 463.48% in 2022, then surged 246.58% in 2025.
- Monte Rosa Therapeutics' Consolidated Net Income stood at -$30.8 million in 2022, then retreated by 8.02% to -$33.3 million in 2023, then jumped by 192.43% to $30.7 million in 2024, then plunged by 195.95% to -$29.5 million in 2025, then tumbled by 51.08% to -$44.6 million in 2026.
- Business Quant data shows GLUE's Consolidated Net Income at -$44.6 million in Q1 2026, -$29.5 million in Q4 2025, and -$27.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Monte Rosa Therapeutics | 1.42 Bn | 785.78 Mn | - | -43.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -43.40 Mn |
| Mar 31, 2026 | -44.55 Mn |
| Dec 31, 2025 | -38.92 Mn |
| Sep 30, 2025 | -27.08 Mn |
| Jun 30, 2025 | -12.30 Mn |
| Mar 31, 2025 | 46.89 Mn |
| Dec 31, 2024 | 30.73 Mn |
| Sep 30, 2024 | -23.86 Mn |
| Jun 30, 2024 | -30.31 Mn |
| Mar 31, 2024 | -31.99 Mn |
| Dec 31, 2023 | -33.25 Mn |
| Sep 30, 2023 | -34.88 Mn |
| Jun 30, 2023 | -35.18 Mn |
| Mar 31, 2023 | -32.04 Mn |
| Dec 31, 2022 | -30.78 Mn |
| Sep 30, 2022 | -27.32 Mn |
| Jun 30, 2022 | -26.47 Mn |
| Mar 31, 2022 | -24.15 Mn |
| Dec 31, 2021 | -23.37 Mn |
| Sep 30, 2021 | -19.86 Mn |